Pemetrexed
- Generic Name
- Pemetrexed
- Brand Names
- Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21N5O6
- CAS Number
- 137281-23-3
- Unique Ingredient Identifier
- 04Q9AIZ7NO
- Background
Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.
- Indication
Pemetrexed is indicated for the treatment of the following conditions:
Non-squamous non-small cell lung cancer (NSCLC)
Malignant pleural mesothelioma
- Associated Conditions
- Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma
- Associated Therapies
- Monotherapy
A Clinical Study on the Safety and Efficacy of Debio 0932 in Combination With Standard of Care in Patients With Non-small Cell Lung Cancer [NSCLC]
- Conditions
- Interventions
- First Posted Date
- 2012-10-25
- Last Posted Date
- 2015-04-08
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 82
- Registration Number
- NCT01714037
- Locations
- 🇫🇷
Centre GF Leclerc, Dijon, France
🇫🇷Institut de Cancérologie de l'Ouest- Institut René Gauduchau, Nantes, France
🇫🇷Centre Léon Bérard, Lyon, France
Reolysin in Previously Treated Advanced/Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy
- Conditions
- Interventions
- First Posted Date
- 2012-10-17
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 166
- Registration Number
- NCT01708993
- Locations
- 🇨🇦
Lakeridge Health Oshawa, Oshawa, Ontario, Canada
🇨🇦Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
🇨🇦Tom Baker Cancer Centre, Calgary, Alberta, Canada
Re-introduction of Pemetrexed and Cisplatin With Prolonged Angiogenic Blocking by Bevacizumab in Advanced Lung Cancer.
- Conditions
- Interventions
- First Posted Date
- 2012-10-12
- Last Posted Date
- 2023-03-13
- Target Recruit Count
- 120
- Registration Number
- NCT01705184
- Locations
- 🇫🇷
Caen - Centre François Baclesse, Caen, France
🇫🇷HCL - Lyon Sud (Pneumologie), Pierre Bénite, France
🇫🇷CH du Mans, Le Mans, France
Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-10-04
- Last Posted Date
- 2014-11-24
- Target Recruit Count
- 13
- Registration Number
- NCT01700400
- Locations
- 🇺🇸
University of Arizona Cancer Center, Tuscon, Arizona, United States
🇺🇸University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States
🇺🇸Providence Cancer Center, Portland, Oregon, United States
TS Stratified Chemotherapy and VEGF Inhibition in Non-Squamous Non-Small Cell Lung Cancer - Stage IV
- Conditions
- Interventions
- First Posted Date
- 2012-08-29
- Last Posted Date
- 2013-10-11
- Lead Sponsor
- Aktion Bronchialkarzinom e.V.
- Registration Number
- NCT01674738
Phase 1b/2 Trial of AMG386 With Pemetrexed and Carboplatin in Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-08-17
- Last Posted Date
- 2016-06-03
- Lead Sponsor
- Amgen
- Target Recruit Count
- 36
- Registration Number
- NCT01666977
- Locations
- 🇪🇸
Research Site, Madrid, Spain
MILES-4: Study Comparing Gemcitabine and Pemetrexed, With or Without Cisplatin, in Patients With Nonsquamous Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-08-03
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- National Cancer Institute, Naples
- Target Recruit Count
- 232
- Registration Number
- NCT01656551
- Locations
- 🇮🇹
Ospedale della Madonna della Navicella, Chioggia, Italy
🇮🇹Ospedale Fabrizio Spaziani, Frosinone, Italy
🇮🇹IRCCS AOU San Martino IST Genova, Genova, Italy
A Study of LY3023414 in Participants With Advanced Cancer
- First Posted Date
- 2012-08-01
- Last Posted Date
- 2022-04-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 156
- Registration Number
- NCT01655225
- Locations
- 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸Penn Presbyterian Medical Center, Philadelphia, Pennsylvania, United States
🇮🇹Azienda Ospedaliero - Universitaria S. Luigi Gonzaga, Orbassano, Torino, Italy
An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations
- Conditions
- Interventions
- First Posted Date
- 2012-07-20
- Last Posted Date
- 2019-07-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 59
- Registration Number
- NCT01646125
- Locations
- 🇺🇸
Cedars Sinai Medical Center Dept.of Cedars-Sinai Med. Ctr., Los Angeles, California, United States
🇬🇧Novartis Investigative Site, Leicester, United Kingdom
🇺🇸Maryland Oncology Hematology, P.A. SC, Rockville, Maryland, United States
A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2012-07-06
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 240
- Registration Number
- NCT01633970
- Locations
- 🇺🇸
Uni of Chicago, Chicago, Illinois, United States
🇺🇸Carolina BioOncology Institute; Can Therapy & Res Ctr, Huntersville, North Carolina, United States
🇺🇸University of Colorado Cancer Center, Aurora, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.